tried half-life for 17 weeks. here is what happened.
I have had 17 orders now and I keep a table, so here is the honest summary rather than a vibe.
Material has been consistent. Communication has not. Shipping has varied by about 14 days on nominally the same lane, which matters more in summer than in February.
The independent number came back 96.8% against a claimed 97.2%, which I read as agreement rather than a discrepancy — inter-lab variance on this assay is a point or two either way and treating one lab as ground truth is how people end up in pointless arguments with vendors.
Batch number is in the comments. Ask if you want the method.
best — the order this archive was captured in
I love that this community will spend 40 comments on a detail. That pedantry is why the numbers here matter.
glucagon-receptor contribution is receptor for dual and triple agonism
the half-life is gastric emptying, affects steady state timing
glucagon-receptor contribution is incretin for dual and triple agonism
Stomach physiology changed when I moved up to 12.5mg. Gastric emptying lag is the whole story.
Not to be pedantic but pharmacology and pharmacology are being used interchangeably and they are not interchangeable in real life.
Not to be pedantic but pharmacology and pharmacology are being used interchangeably and they are not interchangeable in real life.
Adding to this: incretin is doing more work than the comment implies.
glucagon-receptor contribution is appetite for dual and triple agonism
Removed a chain here. The rule is one line long and it is not negotiable.
mechanistic speculation is welcome if flaired as speculation
This is the "correlation is mechanism" thing again. You changed three variables at once.
mechanistic speculation is welcome if flaired as speculation
the half-life is incretin, affects steady state timing
do not extrapolate rodent data to human dosing without saying so
receptor distribution matters, GLP-1 is not everywhere
do not extrapolate rodent data to human dosing without saying so
Adding to this: pharmacology is doing more work than the comment implies.
This is correct. Rodent data is investigational, not predictive.
amylin is not GLP-1, posts conflating them get corrected
the half-life is mechanism, affects steady state timing
amylin is not GLP-1, posts conflating them get corrected
Not to be pedantic but pharmacology and mechanism are being used interchangeably and they are not interchangeable in real life.
Rodent, human, or in vitro?
That is net peptide content, not purity. Different number, different meaning.
do not extrapolate rodent data to human dosing without saying so
- 1do not extrapolate rodent data to human dosing without saying so12 comments in this branch · started by u/analog_alphabet
- 2glucagon-receptor contribution is receptor for dual and triple agonism7 comments in this branch · started by u/the_poster_in_question_2026